|

0.75% MDI-1228_mesylate gel plus Standard of Care Clinical Trials

1 actively recruiting trial across 1 location

Also known as: MDI-1228

Pipeline

Phase 2: 1

Top Sponsors

  • Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.1

Indications

  • Diabetic Foot Ulcer1
  • Diabetes1

Durham, North Carolina1 trial

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

Site 001

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.